Loading clinical trials…
Loading clinical trials…
Clinical trials · failure tracking
Oncology studies whose overall status is TERMINATED, WITHDRAWN or SUSPENDED on ClinicalTrials.gov, with the stop reason exactly as the registrant posted it. A category is attached only when an explicit keyword rule matches the text; CancerIndex never infers why a study stopped.
1,445 stopped studies mapped to Lymphoid Neoplasm and descendants · 89% state a reason
Over the 1,445 studies matching the cancer, status and year filters (the category filter does not change this chart). Each study is counted once, in the first matching category; greyed bars are studies whose text matched no rule or was empty.
Computedrules ci-stop-reasons-v1 · keyword matching only
A category is assigned when one of its keywords appears in the posted text (case-insensitive, whole words). Rules are tested in this order and the first match wins; every match is kept in the API (reasonMatches).
| NCT | Title | Phase | Status | First posted | Lead sponsor | Why stopped (as posted) | Category |
|---|---|---|---|---|---|---|---|
| NCT02420717 | Ruxolitinib Phosphate or Dasatinib With Chemotherapy in Treating Patients With Relapsed… | Phase 2 | terminated | Apr 20, 2015 | M.D. Anderson Cancer Center | Study was closed early due to low accrual and lack of response. | Enrollment / accrual |
| NCT06839872 | A Study to Investigate the Sequencing Strategy of Pirtobrutinib After Disease Progression…(BOSS) | Phase 2 | withdrawn | Feb 21, 2025 | AstraZeneca | AstraZeneca has made the decision to cancel the trial. | Other (stated, no rule matched) |
| NCT04034446 | CD19-CD22 Chimeric Antigen Receptor T (CAR-T) Cell for Treatment of B Cell Acute… | Early Phase 1 | terminated | Jul 26, 2019 | Institute of Hematology & Blood Diseases Hospital, China | Due to adjustments in the company's strategy, the research and development of this project has been… | Sponsor / business decision |
| NCT01350258 | Bone Marrow Transplant Using a Reduced Intensity Regimen That is Given in Two Steps | Phase 1 / Phase 2 | terminated | May 9, 2011 | Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University | Poor accrual | Enrollment / accrual |
| NCT04189952 | Acalabrutinib in Combination With R-ICE For Relapsed or Refractory Lymphoma | Phase 2 | terminated | Dec 6, 2019 | University of Miami | Investigator Decision | Investigator |
| NCT02953509 | Trial of Magrolimab (Hu5F9-G4) in Combination With Rituximab or Rituximab + Chemotherapy… | Phase 1 / Phase 2 | terminated | Nov 2, 2016 | Gilead Sciences | Study terminated early due to the magrolimab program discontinuation. | Other (stated, no rule matched) |
| NCT03432741 | Direct Tumor Microinjection and FDG-PET in Testing Drug Sensitivity in Patients With… | Phase 1 | terminated | Feb 14, 2018 | Mayo Clinic | funding - sponsor filing Chapter 11 bankruptcy | Funding |
| NCT05788289 | A Study of Tafasitamab and Lenalidomide in People With Mantle Cell Lymphoma | Phase 2 | terminated | Mar 28, 2023 | Memorial Sloan Kettering Cancer Center | Slow accrual rate | Enrollment / accrual |
| NCT02811679 | A Study Of Blinatumomab For The Treatment Of Relapsed Or Refractory Indolent Non-Hodgkin… | Phase 2 | terminated | Jun 23, 2016 | Massachusetts General Hospital | Study closed early due to slow accrual | Enrollment / accrual |
| NCT01125449 | Study of High Dose Intravenous (IV) Ascorbic Acid in Measurable Solid Tumor Disease | Phase 2 | withdrawn | May 18, 2010 | Situs Cancer Research Center | Awaiting response from FDA as to status of parenteral ascorbic acid manufactured by Bioniche… | Drug supply |
| NCT04892264 | Belantamab Mafodotin, Lenalidomide, and Daratumumab for the Treatment of Relapsed,… | Phase 1 | terminated | May 19, 2021 | Mayo Clinic | Low/slow accrual - did not proceed to Phase 2 | Enrollment / accrual |
| NCT00626444 | Pilot Trial of Intravenous Vitamin C in Refractory Non-Hodgkin Lymphoma (NHL) | Phase 2 | terminated | Feb 29, 2008 | Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University | Slow accrual | Enrollment / accrual |
| NCT04570631 | Study to Determine Recommended Phase 2 Dose of Intravenous (IV) Eftozanermin Alfa in… | Phase 1 | terminated | Sep 30, 2020 | AbbVie | Strategic considerations | Sponsor / business decision |
| NCT04694560 | A Time-Limited Approach to Treatment With Ibrutinib for Chronic Lymphocytic Leukemia and… | — | withdrawn | Jan 5, 2021 | Memorial Sloan Kettering Cancer Center | Lack of potential participants given the other treatment options currently available to people | Other (stated, no rule matched) |
| NCT03994705 | Descartes-11 in Patients With Relapsed/Refractory Multiple Myeloma | Phase 1 | terminated | Jun 21, 2019 | Cartesian Therapeutics | Phase 1 enrollment completed. Further clinical development terminated. | Enrollment / accrual |
| NCT02966730 | Ibrutinib for Patients With Follicular Lymphoma Without Complete Response to Initial… | Early Phase 1 | terminated | Nov 17, 2016 | Memorial Sloan Kettering Cancer Center | Lack of accrual | Enrollment / accrual |
| NCT04556084 | Blinatumomab Bridging Therapy for BALL | Phase 2 | terminated | Sep 21, 2020 | Michael Burke | poor accrual | Enrollment / accrual |
| NCT02823327 | Clinical and Genomic Factors for Prognosis of AIDS Primary Effusion Lymphoma | — | terminated | Jul 6, 2016 | AIDS Malignancy Consortium | Poor accrual | Enrollment / accrual |
| NCT05038644 | XmAb18968 (CD3-CD38) in Relapsed or Refractory Acute Leukemia and T Cell Lymphoblastic… | Phase 1 | terminated | Sep 9, 2021 | Ehab L Atallah | Drug expired May 31, 2024. | Other (stated, no rule matched) |
| NCT05833737 | Corneal Findings in Patients Treated With Belantamab Mafodotin | — | terminated | Apr 27, 2023 | Medical University of Vienna | Study medication market withdrawal by FDA. | Other (stated, no rule matched) |
| NCT06290622 | PD-1, LAG-3 and TIM-3 Checkpoint Blockade in DLBCL | Phase 1 | withdrawn | Mar 4, 2024 | University of Alabama at Birmingham | Investigator request to no longer pursue this study. Lack of support from drug company. This trial… | Investigator |
| NCT01532635 | A Two-Step Approach to Bone Marrow Transplant Using Cells From Two Partially-Matched… | Phase 2 | terminated | Feb 14, 2012 | Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University | Slow accrual | Enrollment / accrual |
| NCT02548468 | Reduced Intensity Conditioning Before Partially Matched Donor Stem Cell Transplant in… | Phase 1 | withdrawn | Sep 14, 2015 | Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University | Slow accrual | Enrollment / accrual |
| NCT04217317 | CPI-613 in Combination With Bendamustine in Patients With Relapsed/Refractory T-Cell… | Phase 2 | terminated | Jan 3, 2020 | Wake Forest University Health Sciences | Low accruals | Enrollment / accrual |
| NCT04892446 | Study of Magrolimab Combinations in Patients With Relapsed/Refractory Multiple Myeloma | Phase 2 | terminated | May 19, 2021 | Gilead Sciences | This study was terminated early due to the Sponsor's decision to discontinue development of the… | Sponsor / business decision |
| NCT01352312 | Combination of Pentostatin, Bendamustine and Ofatumumab for Treatment of Chronic… | Phase 1 | terminated | May 11, 2011 | Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University | Insufficient accrual over 12 mo period | Enrollment / accrual |
| NCT03288818 | Low Dose Total Skin Electron Beam Radiation Therapy and Mechlorethamine Hydrochloride Gel… | Phase 2 | withdrawn | Sep 20, 2017 | Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University | Funding discontinued | Funding |
| NCT04668365 | Zanubrutinib Combined With Standard Chemotherapy in the Treatment for Patients With… | Phase 2 | suspended | Dec 16, 2020 | Henan Cancer Hospital | Data in analysis | Other (stated, no rule matched) |
| NCT06941688 | Evaluating the Effectiveness of Decitabine With Gemcitabine, Oxaliplatin for… | Phase 2 | terminated | Apr 24, 2025 | Seoul National University Hospital | slow recruitment | Enrollment / accrual |
| NCT02875223 | A Safety and Efficacy Study of CC-90011 in Participants With Relapsed and/or Refractory… | Phase 1 | terminated | Aug 23, 2016 | Celgene | Business objectives have changed | Sponsor / business decision |
| NCT04047797 | Ixazomib and Rituximab in Treating Patients With Relapsed or Refractory Mantle Cell… | Phase 2 | terminated | Aug 7, 2019 | M.D. Anderson Cancer Center | Administratively Complete 75%\<Participants | Other (stated, no rule matched) |
| NCT03486067 | Study of CC-93269, a BCMA x CD3 T Cell Engaging Antibody, in Participants With Relapsed… | Phase 1 | terminated | Apr 3, 2018 | Celgene | Business objectives have changed | Sponsor / business decision |
| NCT03492125 | A Study Of The Selective PKC-β Inhibitor MS- 553 | Phase 1 / Phase 2 | terminated | Apr 10, 2018 | MingSight Pharmaceuticals, Inc | The study is terminated due to major protocol revisions. A new study in CLL patients is planned. | Other (stated, no rule matched) |
| NCT03615105 | Donor Stem Cell Transplantation Using α/β+ T-lymphocyte Depleted Grafts From HLA… | Phase 2 | terminated | Aug 3, 2018 | Memorial Sloan Kettering Cancer Center | Low accrual | Enrollment / accrual |
| NCT04896658 | Belantamab Mafodotin, Cyclophosphamide, and Dexamethasone in Relapsed/Refractory Multiple… | Phase 1 / Phase 2 | terminated | May 21, 2021 | University of Maryland, Baltimore | The study was terminated due to FDA withdrawal of the drug and lack of enrollment with available… | Enrollment / accrual |
| NCT03871829 | Daratumumab Retreatment in Participants With Multiple Myeloma Who Have Been Previously… | Phase 2 | terminated | Mar 12, 2019 | Janssen Research & Development, LLC | The decision was made to discontinue the 54767414MMY2065 study as the Data Review Committee… | Efficacy / futility |
| NCT04251065 | Daratumumab Plus Gemcitabine, Dexamethasone, Cisplatin in pt R/R CD38+ PTCL-NOS, AITL and… | Phase 2 | terminated | Jan 31, 2020 | Fondazione Italiana Linfomi - ETS | The enrolment was prematurely terminated after the planned monitoring of the first 5 patients… | Safety / toxicity |
| NCT04553692 | Phase 1a/1b Study of Aplitabart (IGM-8444) Alone or in Combination in Participants with… | Phase 1 | terminated | Sep 17, 2020 | IGM Biosciences, Inc. | Study terminated due strategic corporate pivot to focus on auto-immune indications | Sponsor / business decision |
| NCT05296525 | Evaluation of Safety and Efficacy of Allo GDA-201 Natural Killer (NK) Cells in Patients… | Phase 1 / Phase 2 | terminated | Mar 25, 2022 | Gamida Cell ltd | Study terminated by Sponsor. | Other (stated, no rule matched) |
| NCT04975399 | Study to Evaluate the Safety and Tolerability of CC-92328 in Participants With Relapsed… | Phase 1 | terminated | Jul 23, 2021 | Celgene | Business objectives have changed | Sponsor / business decision |
| NCT04419389 | APR-246 in Combination With Acalabrutinib or Venetoclax Based Therapy in Subjects With…(R/R) | Phase 1 / Phase 2 | terminated | Jun 5, 2020 | Aprea Therapeutics | Sponsor decision | Sponsor / business decision |
| NCT04982471 | Connect® Lymphoma Disease Registry: A US-Based Prospective Observational Cohort Study | — | terminated | Jul 29, 2021 | Celgene | Slow accrual | Enrollment / accrual |
| NCT03893682 | A Study of CG-806 in Patients With Relapsed or Refractory CLL/SLL or Non-Hodgkin's… | Phase 1 | terminated | Mar 28, 2019 | Aptose Biosciences Inc. | Change in corporate strategy | Sponsor / business decision |
| NCT05486481 | Venetoclax, Daratumumab, and Dexamethasone for Systemic Light-Chain Amyloidosis With… | Phase 1 / Phase 2 | withdrawn | Aug 3, 2022 | Alfred Chung, MD | Industry sponsor unable to continue support | Other (stated, no rule matched) |
| NCT01997840 | ACY-1215 (Ricolinostat) in Combination With Pomalidomide and Low-dose Dex in… | Phase 1 / Phase 2 | terminated | Nov 28, 2013 | Celgene | Change in business priorities. | Sponsor / business decision |
| NCT03457142 | Abatacept, Ixazomib Citrate, and Dexamethasone in Treating Patients With Multiple Myeloma… | Phase 2 | terminated | Mar 7, 2018 | Roswell Park Cancer Institute | funding ended | Funding |
| NCT04750941 | Study of Copanlisib and Ketogenic Diet | Phase 2 | terminated | Feb 11, 2021 | Columbia University | Enrollment challenges | Enrollment / accrual |
| NCT02291965 | Blood Samples to Identify Biomarkers of Busulfan | — | terminated | Nov 17, 2014 | Fred Hutchinson Cancer Center | Study terminated due to end of funding | Funding |
| NCT06352866 | Siltuximab for Cytokine Release Syndrome Prophylaxis Prior to tx w/ Teclistamab in RRMM | Phase 2 | withdrawn | Apr 8, 2024 | Jack Khouri, MD | Funding unavailable | Funding |
| NCT06655818 | Sub-study of Belantamab Mafodotin (GSK2857916) as Monotherapy and in Combination With… | Phase 1 / Phase 2 | terminated | Oct 23, 2024 | GlaxoSmithKline | The study was terminated due to lack of efficacy | Efficacy / futility |
Stop reasons are registrant-reported free text and are displayed verbatim (truncated; hover for the full text). Categories come from explicit keyword rules and are never inferred from the study design, sponsor or outcome; a study that stopped for several reasons is filed under the first rule that matched. A TERMINATED status does not imply a negative result.
Data updated 23 days agoSource updated Jun 8, 2025source: clinicaltrials